Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Azacitidine Post-Transplant for AML/MDS
NCT04128020Phase 1Withdrawn
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of nivolumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms). Primary endpoints: Maximum Tolerated Dose of Nivolumab and Maximum Tolerated Dose of Nivolumab and Azacitidine. Planned start Oct 2019; status: withdrawn.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04128020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128020.